|Bid||7.50 x N/A|
|Ask||7.70 x N/A|
|Day's Range||7.30 - 7.30|
|52 Week Range||4.02 - 23.20|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 2QK.F
Scholar Rock Holding ( NASDAQ:SRRK ) Third Quarter 2022 Results Key Financial Results Net loss: US$43.3m (loss widened...
HC Wainwright has assumed coverage on Scholar Rock Holding Corp (NASDAQ: SRRK) with a Buy rating and price target of $30. The analyst writes that with a positive readout from the Phase 2 TOPAZ study under their belt, Scholar Rock’s apitegromab (SRK-015) is shaping to be a transformative therapeutic for Type 2/3 Spinal Muscular Atrophy (SMA). HC Wainwright says that recent 24-Month TOPAZ extension data further convinces that apitegromab can solidify a place in the SMA market (2025 est. approval)
It is doubtless a positive to see that the Scholar Rock Holding Corporation ( NASDAQ:SRRK ) share price has gained some...